The “Voice of the Patient Report” on the Pemphigus and Pemphigoid Patient-Focused Drug Development Meeting.
To celebrate Rare Disease Day 2024, the IPPF is excited to announce the publication of Understanding the Unmet Needs of the Pemphigus & Pemphigoid Community. This “Voice of the Patient” is a summary of the Externally-Led Patient-Focused Drug Development (EL-PFDD) Meeting on Pemphigus and Pemphigoid held on January 25, 2023. The meeting brought together patients and care partners, US Food and Drug Administration (FDA) representatives, pharmaceutical companies, doctors, and researchers. The goal of the meeting was to hear from patients about what it’s like to live with rare, autoimmune bullous skin diseases so that all involved can better understand the patient experience.
The “Voice of the Patient” report is designed to help the FDA make informed decisions about potential future therapies for pemphigus and pemphigoid. It can also help pharmaceutical companies design therapies and clinical trials to address the aspects of these diseases that are most important to patients.
“Following 2023’s successful EL-PFDD meeting, the ‘Voice of the Patient Report’ is a critical next step in the IPPF’s engagement with the FDA and other decision-makers,” said IPPF Executive Director Patrick Dunn. “As we’ve learned, there are significant obstacles facing pemphigus and pemphigoid patients’ access to potential future therapies. To overcome these obstacles, we must empower the voice of a strong coalition of patients, caregivers, researchers, and clinicians so that regulatory agencies and industry partners understand what truly matters to people living with these diseases.”
This initiative was coordinated by a partnership of pemphigus and pemphigoid patient organizations, including the International Pemphigus & Pemphigoid Foundation (USA), PEM Friends (United Kingdom), Association Pemphigus Pemphigoïde France (France), and the Pemphigus/Pemphigoid Friends Association (Japan).